A APELLIS PHARMACEUTICALS INC
| Market Cap | $2.52B |
| P/E Ratio | 109.67 |
| Forward P/E | -81.23 |
| Dividend Yield | — |
| Beta | 0.29 |
| 52W Range | $16.10 - $30.48 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 34 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| DeLong Mark JeffreyChief Business & Strat Officer | Sale | 368 | $22.15 | $8.15K | 11 Feb 2026 | 13 Feb 2026 |
| Baumal CarolineChief Medical Officer | Sale | 2,797 | $21.77 | $60.88K | 22 Jan 2026 | 23 Jan 2026 |
| Sullivan Timothy EugeneChief Financial Officer | Sale | 10,287 | $21.77 | $223.90K | 22 Jan 2026 | 23 Jan 2026 |
| Watson David O.General Counsel | Sale | 7,832 | $21.77 | $170.47K | 22 Jan 2026 | 23 Jan 2026 |
| DeLong Mark JeffreyChief Business & Strat Officer | Sale | 3,371 | $21.77 | $73.37K | 22 Jan 2026 | 23 Jan 2026 |
| Chopas James GeorgeVP/Chief Accounting Officer | Sale | 2,064 | $21.77 | $44.92K | 22 Jan 2026 | 23 Jan 2026 |
| Francois CedricChief Executive Officer | Sale | 27,192 | $21.77 | $591.84K | 22 Jan 2026 | 23 Jan 2026 |
| Deschatelets PascalChief Scientific Officer | Sale | 5,928 | $21.77 | $129.03K | 22 Jan 2026 | 23 Jan 2026 |
| Nicholson NurChief Technical Officer | Sale | 7,725 | $21.77 | $168.14K | 22 Jan 2026 | 23 Jan 2026 |
| Sullivan Timothy EugeneChief Financial Officer | Sale | 2,892 | $19.79 | $57.24K | 20 Jan 2026 | 21 Jan 2026 |
| Nicholson NurChief Technical Officer | Sale | 2,203 | $19.79 | $43.60K | 20 Jan 2026 | 21 Jan 2026 |
| Deschatelets PascalChief Scientific Officer | Sale | 909 | $19.79 | $17.99K | 20 Jan 2026 | 21 Jan 2026 |
| Francois CedricChief Executive Officer | Sale | 8,182 | $19.79 | $161.95K | 20 Jan 2026 | 21 Jan 2026 |
| DeLong Mark JeffreyChief Business & Strat Officer | Sale | 1,334 | $19.79 | $26.40K | 20 Jan 2026 | 21 Jan 2026 |
| Baumal CarolineChief Medical Officer | Sale | 1,882 | $19.79 | $37.25K | 20 Jan 2026 | 21 Jan 2026 |
| Watson David O.General Counsel | Sale | 2,475 | $19.79 | $48.99K | 20 Jan 2026 | 21 Jan 2026 |
| Chopas James GeorgeVP/Chief Accounting Officer | Sale | 726 | $19.79 | $14.37K | 20 Jan 2026 | 21 Jan 2026 |
| Watson David O.General Counsel | Sale | 5,780 | $22.19 | $128.24K | 13 Jan 2026 | 15 Jan 2026 |
| Francois CedricChief Executive Officer | Sale | 10,186 | $22.19 | $226.00K | 13 Jan 2026 | 15 Jan 2026 |
| Nicholson NurChief Technical Officer | Sale | 2,618 | $22.19 | $58.09K | 13 Jan 2026 | 15 Jan 2026 |
| Chopas James GeorgeVP/Chief Accounting Officer | Sale | 873 | $22.19 | $19.37K | 13 Jan 2026 | 15 Jan 2026 |
| Deschatelets PascalChief Scientific Officer | Sale | 2,277 | $22.19 | $50.52K | 13 Jan 2026 | 15 Jan 2026 |
| Sullivan Timothy EugeneChief Financial Officer | Sale | 3,856 | $22.19 | $85.55K | 13 Jan 2026 | 15 Jan 2026 |
| DeLong Mark JeffreyChief Business & Strat Officer | Sale | 1,780 | $22.19 | $39.49K | 13 Jan 2026 | 15 Jan 2026 |
| Baumal CarolineChief Medical Officer | Sale | 3,020 | $25.53 | $77.10K | 05 Jan 2026 | 06 Jan 2026 |
| Caroline BaumalChief Medical Officer | Sale | 3,020 | $25.53 | $77.10K | 05 Jan 2026 | 06 Jan 2026 |
| Watson David O.General Counsel | Sale | 5,000 | $24.49 | $122.45K | 16 Dec 2025 | 18 Dec 2025 |
| Watson David O.General Counsel | Sale | 5,000 | $20.06 | $100.30K | 17 Nov 2025 | 18 Nov 2025 |
| Sullivan Timothy EugeneChief Financial Officer | Sale | 10,000 | $28.03 | $280.30K | 21 Oct 2025 | 23 Oct 2025 |
| Timothy Eugene SullivanChief Financial Officer | Sale | 10,000 | $28.03 | $280.30K | 21 Oct 2025 | 23 Oct 2025 |
| Watson David O.General Counsel | Sale | 5,000 | $25.22 | $126.10K | 16 Oct 2025 | 17 Oct 2025 |
| David O. WatsonGeneral Counsel | Sale | 5,000 | $25.22 | $126.10K | 16 Oct 2025 | 17 Oct 2025 |
| Dunlop A. Sinclair | Sale | 31,092 | $23.72 | $737.54K | 10 Oct 2025 | 15 Oct 2025 |
| Sinclair A. DunlopDirector | Sale | 31,092 | $23.72 | $737.54K | 10 Oct 2025 | 15 Oct 2025 |
Frequently Asked Questions
What is APLS stock price today?
APELLIS PHARMACEUTICALS INC (APLS) is currently trading at $19.74. The stock has a 52-week range of $16.10 to $30.48 and a market capitalization of $2.52B.
Is APLS a good stock to buy in 2026?
APELLIS PHARMACEUTICALS INC has a P/E ratio of 109.7 (forward P/E: N/A), a dividend yield of none, and 1-year performance of -21.4%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling APLS stock?
There have been 34 insider transactions for APLS in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has APLS stock performed over the past year?
APELLIS PHARMACEUTICALS INC (APLS) has returned -21.4% over the past 12 months. The stock traded between $16.10 and $30.48 during this period, and is currently at $19.74.
Which hedge funds own APLS (APELLIS PHARMACEUTICALS INC)?
0 tracked hedge funds currently hold APLS in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is APLS's market cap and valuation?
APELLIS PHARMACEUTICALS INC (APLS) has a market capitalization of $2.52B. The trailing P/E ratio is 109.7 and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is APLS's revenue and profitability?
APELLIS PHARMACEUTICALS INC reported revenue of $1.00B with net income of $22.39M and a profit margin of 0.02%. The stock has a beta of 0.29.
What sector is APLS in and who are its biggest institutional holders?
APELLIS PHARMACEUTICALS INC (APLS) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.